RaffinoseClinical Trials, Phase III as TopicRazoxaneAntioxidantsGlutathioneProtective AgentsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicClinical Trials, Phase II as TopicOxidative StressTreatment OutcomeRadiation DosageRadiation, IonizingDisease-Free SurvivalCisplatinRadiation InjuriesDrug Administration ScheduleFluorouracilSurvival AnalysisDeoxycytidineAntineoplastic AgentsPaclitaxelCombined Modality TherapyDose-Response Relationship, RadiationChemotherapy, AdjuvantDouble-Blind MethodLung NeoplasmsRadiation ToleranceTaxoidsRadiationVinblastineNeoplasm StagingCarboplatinSurvival RateCarcinoma, Non-Small-Cell LungRadiation ProtectionRandomized Controlled Trials as TopicRadiation MonitoringResearch DesignAntibodies, Monoclonal, HumanizedLeucovorinPlacebosTime FactorsDoxorubicinNeoplasm MetastasisKaplan-Meier EstimateAntimetabolites, AntineoplasticEpirubicinBreast NeoplasmsQuality of LifeCyclophosphamideRadiotherapyRadiotherapy, AdjuvantMulticenter Studies as TopicInfusions, IntravenousRadiotherapy DosageEndpoint DeterminationProspective StudiesClinical Trials, Phase I as TopicFollow-Up StudiesAntineoplastic Agents, PhytogenicPlatinum CompoundsOrganoplatinum CompoundsDose FractionationAntibodies, MonoclonalRadiation OncologyNeoplasmsEarly Termination of Clinical TrialsDisease ProgressionAdenocarcinomaVincristineNeoplasm Recurrence, LocalEtoposidePrognosisCamptothecinDose-Response Relationship, DrugMethotrexateNeutropeniaDrugs, InvestigationalAdministration, OralColorectal NeoplasmsTreatment FailureNeoadjuvant TherapyMaintenance ChemotherapyProportional Hazards ModelsRadiation Injuries, ExperimentalMitomycinNauseaPatient SelectionCosmic RadiationChemoradiotherapyRemission InductionQuinazolinesMedical OncologyCarcinoma, Squamous CellHead and Neck NeoplasmsAntineoplastic Agents, HormonalPrednisoneDacarbazineRadiation Pneumonitis